{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:50:39Z","timestamp":1790059839607,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.diagmicrobio.2017.09.013","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T06:32:49Z","timestamp":1506061969000},"page":"31-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex"],"prefix":"10.1016","volume":"90","author":[{"given":"Zhijian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/JCM.02260-12","article-title":"Comparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom","volume":"51","author":"Broda","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0010","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1086\/322523","article-title":"Successful treatment of disseminated Mycobacterium chelonae infection with linezolid","volume":"33","author":"Brown-Elliott","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0015","series-title":"CLSI document M24-A2","article-title":"Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2011"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2017.09.013_bb0020","first-page":"e1","article-title":"Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies","volume":"34","author":"Entenza","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0030","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccm.2014.10.004","article-title":"The treatment of rapidly growing mycobacterial infections","volume":"36","author":"Kasperbauer","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0924-8579(99)00059-X","article-title":"In vitro activities of the oxazolidinone compounds linezolid (PNU-100766) and eperzolid (PNU-100592) against middle ear isolates of Streptococcus pneumoniae","volume":"12","author":"Kearney","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0045","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2004.06230.x","article-title":"Mycobacterium chelonae infection successfully treated with oral clarithromycin and linezolid","volume":"151","author":"Kyle","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0050","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3201\/2109.141634","article-title":"Mycobacterium abscessus complex infections in humans","volume":"21","author":"Lee","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2017.09.013_bb0055","doi-asserted-by":"crossref","first-page":"ofw201","DOI":"10.1093\/ofid\/ofw201","article-title":"The role of antimicrobial stewardship in the clinical microbiology laboratory: stepping up to the plate","volume":"3","author":"MacVane","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2017.09.013_bb0060","doi-asserted-by":"crossref","first-page":"e00943-16","DOI":"10.1128\/AAC.00943-16","article-title":"Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies","volume":"61","author":"Mougari","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0065","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: a new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0070","doi-asserted-by":"crossref","first-page":"1601429","DOI":"10.1183\/13993003.01429-2016","article-title":"Diversity of nontuberculous mycobacteria in eastern and southern China: a cross-sectional study","volume":"49","author":"Pang","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0924-8579(02)00387-4","article-title":"Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis","volume":"21","author":"Rodriguez Diaz","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0080","doi-asserted-by":"crossref","first-page":"O1124","DOI":"10.1111\/1469-0691.12780","article-title":"In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex","volume":"20","author":"Singh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0085","first-page":"168","article-title":"In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis","volume":"18","author":"Soriano","year":"2005","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0090","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/AAC.45.3.764-767.2001","article-title":"Activities of linezolid against rapidly growing mycobacteria","volume":"45","author":"Wallace","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0095","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s10096-014-2144-5","article-title":"Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China","volume":"33","author":"Zhang","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijantimicag.2016.12.003","article-title":"In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense","volume":"49","author":"Zhang","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ijantimicag.2015.01.012","article-title":"Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China","volume":"45","author":"Zhang","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2013.12.007","article-title":"Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China","volume":"43","author":"Zhang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2017.09.013_bb0115","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s15010-014-0632-2","article-title":"Linezolid in the treatment of extensively drug-resistant tuberculosis","volume":"42","author":"Zhang","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.diagmicrobio.2017.09.013_bb0120","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tube.2015.07.003","article-title":"Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates","volume":"95","author":"Zou","year":"2015","journal-title":"Tuberculosis (Edinb)"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317302870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317302870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:51:51Z","timestamp":1760003511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317302870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0732889317302870"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.09.013","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}